If, they sell infusions for a good price, get a good tavr deal,...

If, they sell infusions for a good price, get a good tavr deal, list immune therapy on the hong kong exchange, many ifs i know, that could easily see our MC over 300 million.

Immune therapy was valued at 30 million, we have received 1 million so far in funding for it, which means legally we still own over 50%, float it on the  Hong Kong exchange like planned and that's at least 20 million if not more. When? Who knows....

A good TAVR deal with money paid upfront will not go unnoticed by the market, the question that remains, these big firms had no interest using our tissue, they saw no problems with their tissue, will they be interested in our TAVR? The market at the moment thinks we have zero chance. The market sentiment is aided by no news from the company. Back in 2016 when they had extra one off spending they explained that in the 4C, fast forward to the last 4C the company now thinks there is zero need to explain the huge extra spend that triggered a further sell off, although privately they are more than happy to explain the extra spending, why not explain it in the 4C so shareholders can access to hold, buy or sell?